Abstract 14167: Clinical Characteristics of Subjects With Different Levels of Systemic Erythrocyte-bound Apolipoprotein B
Introduction: The level of apolipoprotein (apo) B-containing lipoproteins in plasma is positively associated with cardiovascular risk. We have previously demonstrated that apo B bound to circulating erythrocytes (ery-apoB) may protect against atherosclerosis. We evaluated the clinical characteristics of subjects with different levels of ery-apoB.
Methods: Ery-apoB was measured by flow cytometry in subjects with (n=177) and without (n=208) cardiovascular disease (CVD), and expressed as mean fluorescent intensity in arbitrary units (au). The number of criteria for metabolic syndrome as outlined by the NCEP was scored. Carotid intima media thickness (cIMT) was measured using B-mode ultrasound. Data are given as median (IQR).
Results: Ery-apoB was lower in patients with CVD than in controls (0.80 (0.40-1.40) and 0.90 (0.46-1.79) au, respectively, p=0.039). Ery-apoB was inversely associated with cIMT, waist circumference, plasma triglycerides, C-reactive protein and complement C3, and was positively associated with HDL-cholesterol. Ery-apoB was similar in men and women. The number of criteria for the metabolic syndrome was closely associated with ery-apoB, in a dose-depending manner. Median ery-apoB decreased with increasing number of metabolic syndrome criteria (Kruskall Wallis test, p=0.02). Furthermore, ery-apoB was almost 3-fold higher in subjects with blood group O than in subjects with a non-O blood group (1.40 (0.75-2.15) and 0.50 (0.10-0.95) au, respectively, p<0.001). No correlation between ery-apoB and plasma apo B was found, and ery-apoB was unrelated to statin use. Discontinuation of statin use did not affect ery-apoB (n=54).
Conclusion: Apo B bound to circulating erythrocytes is associated with several characteristics of the metabolic syndrome, inflammation and ABO blood group. These data provide novel insight into the mechanisms involved in the binding of atherogenic lipoproteins to erythrocytes.
Author Disclosures: M.A. de Vries: None. B. Klop: None. N. van der Meulen: None. G.M. van de Geijn: None. L. Prinzen: None. E. van der Zwan: None. E. Birnie: None. M. Castro Cabezas: None.
- © 2015 by American Heart Association, Inc.